On May 17, 2023 OmniAb, Inc. (NASDAQ: OABI) reported the launch of OmniDeep at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy Summit (Press release, OmniAb, MAY 17, 2023, View Source [SID1234631818]). The Company introduced elements of its OmniDeep platform at 1:10 p.m. Eastern time today in a presentation by Bob Chen, Ph.D., OmniAb’s Senior Director, Systems Engineering.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
OmniDeep is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. These tools include structural modeling, molecular dynamics simulations, large multi-species antibody databases, artificial intelligence, machine learning, deep learning models and more. OmniDeep facilitates rapid identification of candidates with the right affinity, specificity and developability profiles intended to make drug development more effective and efficient.
"OmniDeep enhances repertoire analysis and further streamlines identification of the most promising therapeutic candidates for our partners. This launch underscores our continued commitment to invest in new technologies and to further innovate around our technology stack," said Matt Foehr, Chief Executive Officer of OmniAb. "This expanded suite adds data-driven adaptable and scalable insights that are valuable to quickly discover novel therapeutics, and we are excited to offer these robust technologies to current and future partners for their discovery programs."
"OmniDeep arose from our long-standing computational biology and in silico-based capabilities, which have been further developed and applied toward the efficient mining of large and diverse antibody repertoires generated through immunization of our proprietary engineered animals," stated Dr. Chen. "As we layer tools like OmniDeep on the broad biological insights from our multiple species of animals, we gain a deeper understanding of the vast antibody repertoires they produce. We believe this knowledge allows us to prioritize and optimize antibodies for performance and developability profiles with the confidence that stems from traceability back to a natural in vivo-evolved antibody."
At the in vivo level, OmniDeep taps into Biological Intelligence, leveraging species-optimized transgenes and structure-focused antigen design to create on-demand repertoires of antibodies that are rich in leads directed toward a partner’s targets of interest. At the in vitro level, OmniDeep’smultiplexed high-throughput single cell phenotypic screening technologies are designed to allow for rapid interrogation of millions of B cells and the nearly immediate identification of functional antibodies. The in silico technologies featured in OmniDeep enhance phenotypic screens through efficient big data processing and provide the ability to go a level deeper into the sequencing space where additional potential lead candidates can exist.
OmniAb will be showcasing OmniDeep and its entire technology stack at the PEGS Conference at booth #413. For more information about OmniDeep and OmniAb’s various proprietary technologies, please visit www.omniab.com or contact our business development team at [email protected].